Biotech ETF XBI likely peaked after 60% rally as key growth drivers fade and momentum slows.

The State Street SPDR S&P Biotech ETF (XBI) has likely reached its peak following a strong 60% rally over the past year. This surge was driven by factors such as breakthrough drug approvals, pharmaceutical mergers and acquisitions, and a favorable low interest rate environment. However, these tailwinds have diminished as interest rates rise and equity supply in biotech hits cycle highs, signaling potential challenges ahead. XBI failed to surpass its 2021 high, and momentum indicators suggest the biotech boom cycle may be ending, implying caution for investors looking for further upside.

Following the news that the biotech rally may have peaked, the State Street SPDR S&P Biotech ETF (XBI) remains below its 52-week high of $169.55, trading at $156.15 on Pluang as of Sep 25, 2026 04:11 WIB. The ETF shows a modest 1-day gain of 0.59%, but Pluang order activity is currently 100% sell, indicating cautious sentiment among investors. Typical holding time on Pluang is 35 days, reflecting relatively short-term engagement with this sector.